Compare Alliant Energy Corporation (LNT) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Sana Biotechnology Inc — how do they compare? Alliant Energy Corporation trades at $65.85 (market cap $16.99B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Alliant Energy Corporation is far larger — about 20.3× Sana Biotechnology Inc's market cap, and Alliant Energy Corporation pays a 3.27% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and Sana Biotechnology Inc for 23 Days on average.
| LNT | SANA | |
|---|---|---|
Market Cap | $16.99B | $836.71M |
Volume | 2,488,387 | 4,507,444 |
Sector | Utilities | Health |
52-Week High | $78.03 | $5.92 |
52-Week Low | $63.21 | $2.68 |
Typical Hold Time | 64 Days | 23 Days |
Enterprise Value | $29.08B | $749.96M |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alliant Energy (LNT) trades at $65.50, up 0.44% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with Q2 2026 EPS beating expectations at $0.65 and consistent revenue growth to $4.36B in 2025. Analyst consensus is positive with a $77.00 price target and 52% buy ratings. Recent institutional activity includes significant purchases by California State Teachers Retirement System and Nykredit A/S.
LNT presents a compelling investment case with stable utility operations, 23-year dividend growth, and a $13.4B capital investment plan supporting 5-7% earnings growth. Key risks include rising debt levels (debt-to-asset ratio increased to 48.48% in 2025) and sensitivity to interest rate changes. The stock offers defensive value with current momentum favoring upside toward analyst targets.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
